Wednesday in The Lancet Microbe.The study focused on infections caused by Aspergillus fumigatus, a fungus that is ubiquitous ...

Researchers from KU Leuven, the University of California Davis Medical Center, the University of Cologne, and over 20 ...

Olorofim, a novel antifungal agent, shows efficacy and tolerability in patients with invasive fungal diseases with limited ...

“We still desperately need this new class of antifungals. Olorofim has great potential to treat fungal infections we currently don’t have treatments for,” she said. Kaitlin Sullivan ...

Since the development of the first antifungals in the 1950s, four main antifungal classes have been indicated for the treatment of IFIs: polyenes, triazoles, echinocandins and pyrimidine analogues.

Antifungal tolerance of C. auris was analyzed against different classes of antifungal drugs, such as fluconazole, amphotericin B, itraconazole, anidulafungin, voriconazole micafungin, caspofungin ...

Scientists at King's have developed a new class of antifungal compounds that could offer a powerful weapon against the rising ...

No new classes of antifungal drugs have become available during the last 20 years, according to a study in the journal Drugs, and only one new agent from a known antifungal class has been approved ...

Olorofim (formerly F901318) is the first in a new class of orotomide antifungal agents intended to provide a new treatment option for serious fungal infections when the current armamentarium of ...

Basilea already secured $29 million to develop its antifungals fosmanogepix and BAL2062, and the Swiss company announced this morning that it has confirmed it will also receive its next tranche of $39 ...

Resistance is nowadays the rule rather than the exception for the four currently available antifungal classes, making it difficult -- if not impossible -- to treat many invasive fungal infections.

In a Class I recall, the most serious type, a New Jersey drugmaker is removing 17,376 drug cartons from the market because of a cross-contamination risk. Scynexis is recalling two lots of ...